Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Nephrology | Urology | Family Medicine

Prostate Cancer Clinical Trials


A listing of Prostate Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

Alabama

Anniston : Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Birmingham :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Birmingham :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Birmingham : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Homewood :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

View More »

Mobile : Providence Cancer Center at Providence Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Muscle Shoals : Investigational Site Number 840002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Muscle Shoals : Investigational Site Number 840004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Alaska

Anchorage : Providence Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Anchorage : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Fairbanks : Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Arizona

Glendale : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Phoenix : Precision Trials, LLC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Phoenix : Caris Science, Inc.

EMBRACE1: Prostate Biorepository

Phoenix : Foundation for Cancer Research and Education

SpaceOAR System Pivotal Study

Phoenix : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

View More »

Phoenix, Mesa, Scottsdale, Glendale : Arizona Oncology Services Foundation

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Scottsdale : 21st Century Oncology

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Scottsdale :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Scottsdale : TGen Clinical Research Services

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Scottsdale :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Tucson :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Tucson :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Tucson : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Tuscon : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Arkansas

Hot Springs : Investigational Site Number 840004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hot Springs : Investigational Site Number 840002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Jonesboro : NEA Medical Clinic - East Matthews

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Little Rock : Arkansas Cancer Research Center at University of Arkansas for Medical Sciences

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

California

Duarte : City of Hope

A Prospective Randomized Trial of Pelvic Drain Placement Versus no Pelvic Drain Placement After Robotic Assisted Laparoscopic Prostatectomy (RALP) in Patients with Prostate Cancer

Duarte : City of Hope

A Randomized, Phase II Study, Assessing Axitinib as Pre-Surgical Therapy in Patients with High Risk Prostate Cancer

Duarte : City of Hope

Assessment of Changes in Inflammatory Cytokines and Downstream Mediators of Prostate Carcinogenesis in Patients Receiving Radiation Therapy for Localized Prostate Cancer

Duarte : City of Hope

Assessment of the Relationship Between Changes in PSA and Peripheral pStat3 Levels, MDSC Quantity and VKOR Mutation in Castrate Resistant Prostate Cancer

Duarte : City of Hope

Long Term Follow Up after Prostate Cancer

Duarte : City of Hope

Pre-Surgical EPS Biomarkers as Predictors of Recurrence

Duarte : City of Hope

Prostate Cancer Database

Duarte : City of Hope

SWOG S1014: Abiraterone Acetate Treatment for Prostate Cancer Patients with a PSA of More Than Four Following Initial Androgen Deprivation Therapy, Phase II

View More »

Anaheim : Investigational Site Number 840008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Anaheim : Investigational Site Number 840009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Anaheim :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Atherton : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Bakersfield : Investigational Site Number 840014

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Baldwin Park :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Beverly Hills : Westside Prostate Cancer Center, University of Southern California

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Burbank :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Burbank :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Campbell : Urological Surgeons of Northern California

SpaceOAR System Pivotal Study

Castro Valley : East Bay Radiation Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Castro Valley : Valley Medical Oncology Consultants - Castro Valley

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Concord : Cancer Care Center at John Muir Health - Concord Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duarte : City of Hope Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Encinitas :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Escondido : San Diego Radiosurgery at Palomar Medical Center Updated

Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer

Fairfield : North Bay Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fontana :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Fremont : Valley Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grass Valley : Sierra Nevada Cancer Center at Sierra Nevada Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hayward :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Highland : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

La Jolla : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

La Mesa : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Laguna Hills : South Orange County Medical Research Center

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Long Beach : Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Long Beach : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Los Angeles :

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Los Angeles : University of California, Los Angeles Institute of Urologic Oncology

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Los Angeles : University of Southern California

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Los Angeles :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Los Angeles : Tower Urology / Tower Research Institute

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Los Angeles : David Geffen School of Medicine at UCLA

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Los Angeles : USC/Norris Comprehensive Cancer Center and Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Los Angeles :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Los Angeles : USC/Norris Comprehensive Cancer Center

Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer

Los Angeles :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Los Angeles : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Marina Del Rey : Prostate Oncology Specialists

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Marina del Rey :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Marina del Rey :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Martinez : Contra Costa Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marysville : Tibotec Therapeutics - Division of Ortho Biotech Products, LP

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Merced : Mercy Cancer Center at Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Modesto : Investigational Site Number 840030

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Montebello : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Mountain View : El Camino Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Murrieta : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Oakland : Alta Bates Summit Medical Center - Summit Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Highland General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Bay Area Breast Surgeons, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : CCOP - Bay Area Tumor Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Epic Care - Oakland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Larry G Strieff MD Medical Corporation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland : Tom K Lee, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oakland :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Orange : St. Joseph Hospital Regional Cancer Center - Orange

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Orange : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Orange : Chao Comprehensive Cancer Center

Trail of Taxotere Plus Sunitinib on Newly Diagnosed, Hormone Refractory, Metastatic Prostate Cancer

Palo Alto :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Pleasanton : Valley Medical Oncology Consultants - Pleasanton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rancho Mirage : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Roseville :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Sacramento : University of California Davis Cancer Center

Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

Sacramento : University of California Davis Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sacramento :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Sacramento : Radiological Associates of Sacramento

SpaceOAR System Pivotal Study

Sacramento : University of California at Davis

Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer

San Bernardino : San Bernardino Urological Associates

A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

San Bernardino : Investigational Site Number 840001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

San Bernardino : Investigational Site Number 840003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

San Bernardino :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Bernardino : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

San Diego :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

San Diego : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

San Diego : Sharp Health Care

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

San Diego : Genesis Research

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

San Diego :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

San Diego :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Diego :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

San Diego : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

San Diego : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

San Diego : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

San Francisco :

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

San Francisco : University of California, San Francisco

Abiraterone Post Ketoconazole for Prostate Cancer

San Francisco : Investigational Site Number 840001

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

San Francisco : Investigational Site Number 840010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

San Francisco : Investigational Site Number 840012

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

San Francisco : California Pacific Medical Center Research Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

San Francisco :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

San Francisco : University of California, San Francisco

Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC

San Francisco :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Francisco : University of California San Francisco (UCSF) Medical Center

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

San Jose :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Luis Obispo : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

San Marcos :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Pablo : Doctors Medical Center - San Pablo Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Santa Clara :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Santa Monica : University of California Los Angeles (UCLA)

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

South San Francisco :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Stanford :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Stockton : Investigational Site Number 840022

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Torrance :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Torrance : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Truckee : Tahoe Forest Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Vallejo :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Vallejo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Walnut Creek : John Muir/Mt. Diablo Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Walnut Creek :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Colorado

Denver : The Urology Center of Colorado

A Phase 4, placebo controlled study to evaluate the efficacy and safety of VESIcare to improve urinary incontinence in men after robotic assisted radical prostatectomy

Denver : The Urology Center of Colorado

A Phase 4, placebo controlled study to evaluate the efficacy and safety of VESIcare to improve urinary incontinence in men after robotic assisted radical prostatectomy

Denver : The Urology Center of Colorado

A Phase II study of Abiraterone Acetate plus Prednisone in subjects with advanced prostate cancer without radiographic evidence of metastatic disease

Denver : The Urology Center of Colorado

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

Denver : The Urology Center of Colorado

International, open label, randomized study assessing the safety and efficacy of a monthly dosing regimen of Ozarelix vs. Goserlin Depot (Zoladex) in men with prostate cancer.

Denver : The Urology Center of Colorado

Open, non-randomized, uncontrolled, multiple dose escalation study of the safety and effectiveness of an investigational drug (ODM-201) for men with advanced prostate cancer.

Denver : The Urology Center of Colorado

Phase 2 multicenter prospective open label, 2- dose level clinical trial studying the safety and efficacy of an injection of NX-1207 for the treatment of low risk, localized (T1c) prostate cancer.

Denver : The Urology Center of Colorado

Phase II efficacy and safety study of MDV3100 vs. bicalutamide in castrate men with metastatic prostate cancer

Denver : The Urology Center of Colorado

Phase II, double blind, efficacy and safety study of Enzalutamide vs. Bicalutamide in men with prostate cancer who have failed primary androgen deprivation therapy.

Denver : The Urology Center of Colorado

Study to Evaluate New or Worsening Lens Opacifications in Subjects with Nonmetastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy

View More »

Aurora :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Aurora : Aurora Presbyterian Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Aurora :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Aurora : University of Colorado Cancer Center

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Aurora : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Aurora : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Boulder : Rocky Mountain Cancer Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Boulder : Boulder Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Colorado Springs : Memorial Hospital Cancer Center - Colorado Springs

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Colorado Springs : Penrose Cancer Center at Penrose Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Denver : Investigational Site Number 840019

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Denver :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Denver : The Urology Center of Colorado

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Denver : The Urology Center of Colorado

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Denver : Genitourinary Surgical Consultants

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Denver : Porter Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : St. Joseph Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : CCOP - Colorado Cancer Research Program

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Presbyterian - St. Luke's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : Rose Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver : St. Anthony Central Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Denver :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Denver : The Urology Center of Colorado

SpaceOAR System Pivotal Study

Denver : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Englewood : Swedish Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Englewood : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Fort Collins : Front Range Cancer Specialists

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Collins : Poudre Valley Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Golden : Foothills Urology

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Grand Junction : St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greeley : North Colorado Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Littleton : Littleton Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Littleton :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Lone Tree : Sky Ridge Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Longmont : Hope Cancer Care Center at Longmont United Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Loveland : McKee Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Parker : Advanced Urology

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Parker : Parker Adventist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pueblo : St. Mary - Corwin Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Thornton : North Suburban Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wheat Ridge : Exempla Lutheran Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wheat Ridge : The Urology Center of Colorado

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Wheat Ridge : The Urology Center of Colorado

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Connecticut

Hartford : Investigational Site Number 840031

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Hartford : Hartford Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Hartford : Saint Francis Hospital and Medical Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Hartford : Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Middlebury : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

View More »

Middlebury : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

New Britain : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

New Britain : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

New Haven :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Norwalk :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Norwich : Eastern CT Hematology and Oncology Associates

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Norwich : Eastern CT Hematology and Oncology Associates

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Southington : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Stamford : Investigational Site Number 840021

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stamford : Investigational Site Number 840029

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Delaware

Lewes : Tunnell Cancer Center at Beebe Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newark : Helen F. Graham Cancer Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Newark : CCOP - Christiana Care Health Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

District of Columbia

Washington :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Washington :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Florida

Aventura : South Florida Medical Research

Metastatic, Androgen-Independent study for patients with Prostate Cancer

Aventura : South Florida Medical Research, Inc.

Phase IV, Hormone Refractory Prostate Cancer Study

Fort Lauderdale : Holy Cross Hospital

AT13387-04

Tallahassee : Southeastern Research Group, Inc.

Prostate Cancer - A Phase III, Open-Label Trial of Degarelix Intermittent Therapy vs. Continuous Androgen Deprivation Therapy with Leuprolide or Degarelix in patients with carcinoma of the prostate with biochemical failure after localized therapy

Tampa : H. Lee Moffitt Cancer Center & Research Institute

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

View More »

Aventura :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Aventura : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Aventura : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Boca Raton : Investigational Site Number 840013

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Boca Raton :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Bradenton : Lakewood Ranch Oncology Center/21st Century Oncology

SpaceOAR System Pivotal Study

Daytona Beach : Atlantic Urological Associates

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Daytona Beach :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Fort Lauderdale : Holy Cross Hospital

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Fort Lauderdale : Broward General Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Meyers : 21st Century Oncology

SpaceOAR System Pivotal Study

Fort Myers : Florida Cancer Specialists

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Fort Myers : 21st Century Oncology

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Inverness : Florida Cancer Specialists

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Jacksonville : Investigational Site Number 840023

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Jacksonville : Investigational Site Number 840035

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Jacksonville :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Lakeland : Lakeland Regional Cancer Center

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Lakeland : Investigational Site Number 840013

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Naples :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Naples : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Ocala : Urology Health Team

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Orange City : Atlantic Urological Associates

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Orange City :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Orange City :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Orlando : MD Anderson-Orlando-Orlando Health

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Orlando : Winter Park Urology Associates, PA

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Orlando : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Pensacola : Sacred Heart Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pensacola : Sacred Heart Cancer Center at Sacred Heart Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Port St. Lucie :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Port St. Lucie : Investigational Site Number 840003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Port St. Lucie : Investigational Site Number 840001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Sarasota : Florida Urology Specialists

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Sarasota : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

St Petersburg : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Tampa : H. Lee Moffitt Cancer Center and Research Institute

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

Tampa : H. Lee Moffitt Cancer Center and Research Institute at University of South Florida

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tampa : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Titusville : Space Coast Medical Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Trinity : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Wellington : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

West Palm Beach : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Georgia

Savannah : Memorial University Medical Center

SWOG S1014: Phase II Abiraterone Acetate Treatment for Prostate Cancer Patients With a PSA of More Than Four Following Initial Androgen Deprivation Therapy

View More »

Athens : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Atlanta : Piedmont Healthcare Research Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Atlanta :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Atlanta : CCOP - Atlanta Regional

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Piedmont Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Northside Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Saint Joseph's Hospital of Atlanta

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Atlanta : Emory University

SpaceOAR System Pivotal Study

Atlanta : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Austell : WellStar Cobb Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : John B. Amos Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Decatur : Charles B. Eberhart Cancer Center at DeKalb Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fayetteville : Piedmont Fayette Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fayetteville : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Gainesville : Northeast Georgia Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lawrenceville : Gwinnett Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta : Georgia Cancer Specialists, P.C.

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Marietta : Kennestone Cancer Center at Wellstar Kennestone Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Riverdale : Southern Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rome : Harbin Clinic Cancer Center - Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Savannah : Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Valdosta : Pearlman Comprehensive Cancer Center at South Georgia Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hawaii

Aiea : Kapiolani Medical Center at Pali Momi

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Kapiolani Medical Center for Women and Children

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : OnCare Hawaii, Incorporated - Lusitana

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Straub Clinic and Hospital, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Cancer Research Center of Hawaii

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Honolulu : Hawaii Medical Center - East

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : OnCare Hawaii, Incorporated - Kuakini

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Queen's Cancer Institute at Queen's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Honolulu : Tripler Army Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lihue : Kauai Medical Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wailuku : Pacific Cancer Institute - Maui

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wailuku : Maui Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Idaho

Boise : Mountain States Tumor Institute at St. Luke's Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Boise : Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Coeur d'Alene : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Coeur d'Alene : North Idaho Urology

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Fruitland : Saint Luke's Mountain States Tumor Institute - Fruitland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Lewiston : St. Joseph Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Meridian : Idaho Urologic Institute

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Meridian : Mountain States Tumor Institute - Meridian

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Nampa : Saint Luke's Mountain States Tumor Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Twin Falls : Mountain States Tumor Institute at St. Luke's

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Illinois

Elgin : Sherman Health

ECOG E2809 Phase II Randomized Study of Bicalutamide With Versus Without Akt Inhibitor MK2206 in Patients With Prostate Cancer and Rising PSA at High-Risk of Progression After Primary Therapy

Elgin : Sherman Health

ECOG E3805 Phase III Randomized Study of Chemohormonal Therapy Versus Androgen-Ablation Therapy in Patients With Extensive Metastatic Prostate Cancer

Elgin : Sherman Health

SWOG S0925 Phase II Randomized Study of Combined Androgen Deprivation Comprising Bicalutamide and Goserelin or Leuprolide Acetate With Versus Without Cixutumumab in Patients With Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer

Elgin : Sherman Health

SWOG S1014 Phase II Study of Abiraterone Acetate in Patients With Metastatic Prostate Cancer and a Sub-Optimal Prostate-Specific Antigen Following Initial Androgen-Deprivation Therapy

Elk Grove Village : Alexian Brothers Hospital Network

A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel.

View More »

Aurora : Rush-Copley Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Carbondale : Memorial Hospital of Carbondale

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago :

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Chicago : University of Chicago

Abiraterone Post Ketoconazole for Prostate Cancer

Chicago : The University of Chicago

Pazopanib, Docetaxel, Prednisone Prostate

Chicago : John H. Stroger, Jr. Hospital of Cook County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : Louis A. Weiss Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chicago : Northwestern University

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Chicago :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Decatur : Investigational Site Number 840015

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Decatur : Decatur Memorial Hospital Cancer Care Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elgin : Sherman Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Evanston :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Evanston : Evanston Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Evanston : North Shore University

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Galesburg :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Galesburg : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Geneva : Delnor Hospital - Geneva

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Glenview :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Hines : Veterans Affairs Medical Center - Hines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maywood : Cardinal Bernardin Cancer Center at Loyola University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Melrose Park : Uropartners/RMD Clinical Research

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Melrose Park :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Moline : Trinity Cancer Center at Trinity Medical Center - 7th Street Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Moline :

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Good Samaritan Regional Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Niles : Oncology Specialists, SC

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

Niles : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Park Ridge : Oncology Specialists, S.C.

Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients

River Forest : West Suburban Center for Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springfield : Southern Illinois University School of Medicine

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Springfield : Regional Cancer Center at Memorial Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Urbana : CCOP - Carle Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Warrenville : Central Dupage Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Indiana

Beech Grove : St. Francis Hospital and Health Centers - Beech Grove Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Elkhart Clinic, LLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Elkhart General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elkhart : Michiana Hematology-Oncology, PC - Elkhart

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Wayne :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

View More »

Greenwood : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Greenwood : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Indianapolis : Indiana University School of Medicine

Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling

Indianapolis : Indiana University Simon Cancer Center

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Indianapolis :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Jeffersonville : First Urology

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Jeffersonville :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Jeffersonville :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Jeffersonville : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Jeffersonville : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Kokomo : Howard Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

La Porte : Center for Cancer Therapy at LaPorte Hospital and Health Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Michigan City : Saint Anthony Memorial Health Centers

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mishawaka : Michiana Hematology-Oncology, PC - South Bend

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mishawaka : Saint Joseph Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Plymouth : Michiana Hematology Oncology PC - Plymouth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Richmond : Reid Hospital & Health Care Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

South Bend : CCOP - Northern Indiana CR Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

South Bend : Memorial Hospital of South Bend

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Westville : Michiana Hematology Oncology PC - La Porte

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Iowa

Ames : McFarland Clinic, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bettendorf :

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar Rapids : Cedar Rapids Oncology Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar Rapids : Mercy Regional Cancer Center at Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Clive : Medical Oncology and Hematology Associates - West Des Moines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Davenport : Genesis Regional Cancer Center at Genesis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : John Stoddard Cancer Center at Iowa Lutheran Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Medical Oncology and Hematology Associates at Mercy Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : CCOP - Iowa Oncology Research Association

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : John Stoddard Cancer Center at Iowa Methodist Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Medical Oncology and Hematology Associates at John Stoddard Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Des Moines : Mercy Cancer Center at Mercy Medical Center - Des Moines

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mason City : Mercy Cancer Center at Mercy Medical Center - North Iowa

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : Mercy Medical Center - Sioux City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : Siouxland Hematology-Oncology Associates, LLP

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : St. Luke's Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sioux City : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

West Des Moines : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Kansas

Chanute : Cancer Center of Kansas, PA - Chanute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dodge City : Cancer Center of Kansas, PA - Dodge City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

El Dorado : Cancer Center of Kansas, PA - El Dorado

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fort Scott : Cancer Center of Kansas - Fort Scott

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Independence : Cancer Center of Kansas-Independence

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Kingman : Cancer Center of Kansas, PA - Kingman

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lawrence : Lawrence Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Liberal : Cancer Center of Kansas, PA - Liberal

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

McPherson : Cancer Center of Kansas, PA - McPherson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newton : Cancer Center of Kansas, PA - Newton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Overland Park : Kansas City Urology Care, PA

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Overland Park : Menorah Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Overland Park : Saint Luke's Hospital - South

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Parsons : Cancer Center of Kansas, PA - Parsons

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Prairie Village : CCOP - Kansas City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pratt : Cancer Center of Kansas, PA - Pratt

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salina : Cancer Center of Kansas, PA - Salina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salina : Tammy Walker Cancer Center at Salina Regional Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Topeka : Cotton-O'Neil Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wellington : Cancer Center of Kansas, PA - Wellington

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Westwood :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Wichita : Investigational Site Number 840018

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Wichita : Cancer Center of Kansas

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Wichita : Cancer Center of Kansas

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Wichita : Cancer Center of Kansas, PA - Wichita

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Associates in Womens Health, PA - North Review

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Cancer Center of Kansas, PA - Medical Arts Tower

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : CCOP - Wichita

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Via Christi Cancer Center at Via Christi Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wichita : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Winfield : Cancer Center of Kansas, PA - Winfield

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kentucky

Hazard : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Louisville : Baptist Hospital East

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Louisville :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Paducah : Investigational Site Number 840010

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Louisiana

Baton Rouge : Ochsner Health Center - Bluebonnet

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Covington : Ochsner Health Center - Covington

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Matairie :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Monroe : Louisiana State University Health Sciences Center - Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

View More »

New Orleans : Investigational Site Number 840007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

New Orleans : Investigational Site Number 840008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

New Orleans :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

New Orleans : Tulane University

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

New Orleans : CCOP - Ochsner

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans : Ochsner Cancer Institute at Ochsner Clinic Foundation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

New Orleans :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Shreveport : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Shreveport : Feist-Weiller Cancer Center at Louisiana State University Health Sciences

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Shreveport : Highland Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Shreveport :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Shreveport : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Maryland

Annapolis : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Annapolis : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Baltimore : University of Maryland, Greenebaum Cancer Center

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Baltimore : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Baltimore : Johns Hopkins University

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

View More »

Baltimore : Investigational Site Number 840014

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Baltimore : The Johns Hopkins University School of Medicine, The Sidney Kimmel Comprehensive Cancer Center

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Baltimore : Johns Hopkins Medical Institutions

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Baltimore : Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Baltimore : Johns Hopkins University Department of Radiation Oncology and Molecular Radiation Sciences

SpaceOAR System Pivotal Study

Baltimore :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Baltimore : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Bethesda : Center for Cancer & Blood Disorders

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Bethesda : National Institutes of Health Clinical Center, 9000 Rockville Pike

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

Bethesda : Walter Reed National Military Medical Center

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Bethesda : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Elkton MD : Union Hospital of Cecil County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenbelt : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Greenbelt : Mid Atlantic Clinical Research

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Owings Mills : Chesapeake Urology Associates, Chesapeake Urology Research Associates (The Prostate Center)

SpaceOAR System Pivotal Study

Rockville :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Rockville : Investigational Site Number 840005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Rockville : Investigational Site Number 840006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Rockville :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Towson :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Towson :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Towson : GTX Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Massachusetts

Boston : Dana-Farber Cancer Institute

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Boston : Beth-Israel Deaconess Medical Center

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Boston : Investigational Site Number 840138

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Boston : Investigational Site Number 840238

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Boston : Boston University Medical Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

View More »

Boston : Dana-Farber Cancer Institute and (Sanofi-Aventis Consortium)

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Boston :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Boston : Beth Israel Deaconess Medical Center

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

Boston : Dana-Farber Cancer Institute

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer

Boston : Massachusetts General Hospital Cancer Center

Safety Study of MGA271 in Refractory Cancer

Boston : Dana-Farber Cancer Institute

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

Boston : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Boston :

Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Brookline : Investigational Site Number 840038

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Methuen : Caritas Holy Family Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Methuen : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Rockland : Contact US Medical Information in Rockland, MA for US Recruiting Sites

L-BLP25 (Stimuvax) in Prostate Cancer

Worcester : University of Massachusetts Medical School

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Michigan

Ann Arbor : University of Michigan

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

View More »

Adrian : Hickman Cancer Center at Bixby Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : Saint Joseph Mercy Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : CCOP - Michigan Cancer Research Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : University of Michigan Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ann Arbor : University of Michigan Health System

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Ann Arbor : University of Michigan Comprehensive Cancer Center

Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer

Ann Arbor : University of Michigan Health System

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Battle Creek : Battle Creek Health System Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bay City : Bay Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Big Rapids : Mecosta County Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dearborn : Oakwood Cancer Center at Oakwood Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Detroit :

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Detroit : Karmanos Cancer Institute

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Detroit : Investigational Site Number 840005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Detroit : Karmanos Cancer Institute

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Detroit : Josephine Ford Cancer Center at Henry Ford Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Detroit : Wayne State (Karmanos Cancer Institute)

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Detroit :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Detrot :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Escanaba : Green Bay Oncology, Limited - Escanaba

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Genesys Hurley Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Hurley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : McLaren Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Flint : Singh and Arora Hematology Oncology, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : Butterworth Hospital at Spectrum Health

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : CCOP - Grand Rapids

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grand Rapids : Lacks Cancer Center at Saint Mary's Health Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grosse Pointe Woods : Van Elslander Cancer Center at St. John Hospital and Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Iron Mountain : Dickinson County Healthcare System

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jackson : Foote Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : Bronson Methodist Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : Borgess Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalamazoo : West Michigan Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lansing :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Lansing : Breslin Cancer Center at Ingham Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lansing : Sparrow Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lapeer : Great Lakes Cancer Institute - Lapeer Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Livonia : St. Mary Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Monroe : Community Cancer Center of Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Monroe : Mercy Memorial Hospital - Monroe

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Clemens : Clemens Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Muskegon : Mercy General Health Partners

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Petoskey : Northern Michigan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pontiac : St. Joseph Mercy Oakland

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Port Huron : Mercy Regional Cancer Center at Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Reed City : Spectrum Health Reed City Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Royal Oak : William Beaumont Hospital - Royal Oak Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saginaw : Seton Cancer Institute at Saint Mary's - Saginaw

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Joseph : Lakeside Cancer Specialists, PLLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Joseph : Lakeland Regional Cancer Care Center - St. Joseph

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Southfield : Providence Cancer Institute at Providence Hospital - Southfield Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Traverse City : Munson Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Troy :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Warren : St. John Macomb Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wyoming : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Minnesota

Brainerd : St. Joseph's Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Burnsville : Fairview Ridges Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Coon Rapids : Mercy and Unity Cancer Center at Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : Duluth Clinic Cancer Center - Duluth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Duluth : CCOP - Duluth

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Duluth : Miller - Dwan Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Edina : Fairview Southdale Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Fridley : Mercy and Unity Cancer Center at Unity Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Hutchinson : Hutchinson Area Health Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maplewood : HealthEast Cancer Care at St. John's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maplewood : Minnesota Oncology - Maplewood

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : Hennepin County Medical Center - Minneapolis

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Minneapolis : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

New Ulm : New Ulm Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Robbinsdale : Humphrey Cancer Center at North Memorial Outpatient Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rochester : Mayo Clinic

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Saint Louis Park : CCOP - Metro-Minnesota

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis Park : Park Nicollet Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Paul : United Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sartell : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Shakopee : St. Francis Cancer Center at St. Francis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

St Louis Park : Investigational Site Number 840017

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

St Louis Park : Investigational Site Number 840021

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

St. Paul : Regions Hospital Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Stillwater : Lakeview Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Waconia : Ridgeview Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Willmar : Willmar Cancer Center at Rice Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Woodbury : Minnesota Oncology - Woodbury

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mississippi

Jackson : Investigational Site Number 840011

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Jackson : University of Mississippi Cancer Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jackson : Veterans Affairs Medical Center - Jackson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pascagoula : Regional Cancer Center at Singing River Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Missouri

Cape Girardeau : Southeast Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cape Girardeau : Saint Francis Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jefferson City : Goldschmidt Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Jefferson City : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Kansas City : Investigational Site Number 840016

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

View More »

Kansas City : North Kansas City Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Saint Luke's Cancer Institute at Saint Luke's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Veterans Affairs Medical Center - Kansas City

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Heartland Hematology Oncology Associates, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kansas City : Research Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lee's Summit : Saint Luke's East - Lee's Summit

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Liberty : Parvin Radiation Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Joseph : Heartland Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Joseph : Saint Joseph Oncology, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : CCOP - St. Louis-Cape Girardeau

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : Christian Hospital Northeast Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : David C. Pratt Cancer Center at St. John's Mercy

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : Midwest Hematology Oncology Group, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : Missouri Baptist Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint Louis : Saint Louis University Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springfield : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

St Louis : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

St. Louis : Washington University School of Medicine

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

St. Louis : Washington University School of Medicine

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

St. Louis :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

St. Louis :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Montana

Billings : Frontier Cancer Center and Blood Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Billings : CCOP - Montana Cancer Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : Billings Clinic - Downtown

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : Hematology-Oncology Centers of the Northern Rockies - Billings

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Billings : St. Vincent Healthcare Cancer Care Services

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Bozeman : Bozeman Deaconess Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Butte : St. James Healthcare Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Great Falls : Big Sky Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Great Falls : Sletten Cancer Institute at Benefis Healthcare

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Helena : St. Peter's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalispell : Kalispell Medical Oncology at KRMC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kalispell : Kalispell Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Missoula : Montana Cancer Center at St. Patrick Hospital and Health Sciences Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Missoula : Montana Cancer Specialists at Montana Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Missoula : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Nebraska

Kearney : Good Samaritan Cancer Center at Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lincoln : Investigational Site Number 840016

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lincoln : Investigational Site Number 840020

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lincoln : Cancer Resource Center - Lincoln

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lincoln : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

View More »

Omaha : Urology Cancer Center and GU Research Network

A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Omaha :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Omaha : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Omaha : Urology Cancer Center and GU Research Network

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Omaha :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Omaha : Alegant Health Cancer Center at Bergan Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Immanuel Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : CCOP - Missouri Valley Cancer Consortium

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Creighton University Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha : Lakeside Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Omaha :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Omaha : Urology Cancer Center, PC

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer

Omaha : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Nevada

Las Vegas : Comprehensive Cancer Centers of Nevada

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Las Vegas : CCOP - Nevada Cancer Research Foundation

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Las Vegas : Nevada Cancer Institute

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Las Vegas : University Medical Center of Southern Nevada

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Las Vegas :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

View More »

Reno : Northern Nevada Radiation Oncology

SpaceOAR System Pivotal Study

New Jersey

Lawrenceville : AdvanceMed Research

A Clinical Research Study for Advanced Prostate Cancer is Currently Enrolling

Lawrenceville : AdvanceMed Research

Prostate Cancer that requires Hormone therapy.

View More »

Berlin : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Brick : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

East Orange : Department Of Veterans Affairs NJ Health Care System

A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer

East Orange : Department of Veterans Affairs NJ Health Care System

A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

East Orange : Investigational Site Number 840015

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

East Orange : Investigational Site Number 840017

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Englewood : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Freehold : CentraState Medical Center

SpaceOAR System Pivotal Study

Hamilton : Premier Urology Associates, LLC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Lawrenceville : Premier Urology Associates, LLC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Lawrenceville : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Mount Laurel : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

New Brunswick : Cancer Institute of New Jersey

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

New Brunswick : The Cancer Institute of New Jersey

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

New Brunswick : The Cancer Institute of New Jersey

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

New Brunswick : The Cancer Institute of New Jersey

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Newark : UMDNJ University Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Voorhees : Cooper University Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Voorhees : Delaware Valley Urology

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Voorhees : Cancer Institute of New Jersey at Cooper - Voorhees

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Voorhees : Delaware Valley urology, LLC

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Voorhees : Delaware Valley urology, LLC

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

New Mexico

Albuquerque : Urology Group of New Mexico

Prostate Cancer with/without bone metastasis

View More »

Albuquerque : Investigational Site Number 840033

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Albuquerque : University of New Mexico Cancer Center

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Albuquerque : Hematology Oncology Associates, PC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Albuquerque : University of New Mexico Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Albuquerque : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

New York

Bronx : Biomedical Research Alliance of New York

Prostate Cancer - Adult Men

Garden City : Advanced Urology Centers of New York, Garden City Central Research Department

For Men with Non-Metastatic Prostate Cancer: A Clinical Trial That Might Interest You

Garden City : Advanced Urology Centers of New York, Garden City Central Research Department

Phase 2, MultiCenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the treatment of Low Risk, Localized (T1c) Prostate Cancer

View More »

Albany : The Urological Institute of Northeastern New York

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Albany :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Albany : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Albany : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Bronx : Albert Einstein Medical Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Brooklyn : Brooklyn Urology Research Group

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Brooklyn :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Buffalo : Roswell Park Cancer Institute

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Buffalo :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Buffalo :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

East Setauket : National Translational Research Group, Inc.

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

East Syracuse : CCOP - Hematology-Oncology Associates of Central New York

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elmira : Falck Cancer Center at Arnot Ogden Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Erie, Niagara, and Chautauqua County : Western New York Urology Associates, LLC and D/B/A Cancer Care of WNY

SpaceOAR System Pivotal Study

Garden City : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Garden City :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Garden City :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Garden City : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Garden City : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Lake Success : Clinical Research Alliance, Inc.

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Lake Success : Monter Cancer Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Lake Success : North Shore University Hospital-Monter Cancer Center

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Lake Success : Advanced Radiation Centers of New York

SpaceOAR System Pivotal Study

New Hyde Park : The Arthur Smith Institute for Urology

MRI/TRUS Fusion Guided Prostate Biopsy- An Improved Way to Detect and Quantify Prostate Cancer

New York : Memorial Sloan-Kettering Cancer Center

3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

New York : New York Presbyterian Hospital, Weill Cornell Medical College

99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

New York : Memorial Sloan Kettering Cancer Center

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

New York :

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

New York : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

New York : Memorial Sloan-Kettering Cancer Center

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

New York : Investigational Site Number 840022

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

New York : Investigational Site Number 840034

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

New York : Memorial Sloan Kettering Cancer Center

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

New York : Memorial Sloan Kettering Cancer Center

Degarelix Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

New York : University Urology Associates

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

New York :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

New York : Memorial Sloan-Kettering Cancer Center

Molecular Studies and Clinical Correlations in Human Prostatic Disease

New York : Memorial Sloan Kettering Cancer Center

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

New York : NYU Cancer Center

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

New York : Memorial Sloan Kettering Cancer Center

Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer

New York :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

New York : Memorial Sloan-Kettering Cancer Center

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

New York : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Oneida : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Poughkeepsie : The Premier Medical Group of the Hudson Valley, PC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Poughkeepsie :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Poughkeepsie :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Rochester : James P. Wilmot Cancer Center at University of Rochester Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Rochester : University of Rochester

SpaceOAR System Pivotal Study

Staten Island : Staten Island Urological Research, PC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Staten Island :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Syracuse : SUNY Upstate Medical University

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Syracuse : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Syracuse : SUNY Upstate Medical University

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Syracuse : Associated Medical Professionals of NY, PLLC

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Syracuse :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Syracuse : Associated Medical Professionals of NY

SpaceOAR System Pivotal Study

Syracuse : Upstate Medical University

SpaceOAR System Pivotal Study

Syracuse : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

North Carolina

Charlotte : USHIFU

A multicenter clinical study of the Sonablate® 500 (Sonablate) for the TreAtment of locally Recurrent prostate cancer with HIFU(STAR Trial)

Durham : Duke University

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

View More »

Asheville : Mission Hospitals - Memorial Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Chapel Hill :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Chapel Hill :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Charlotte : Blumenthal Cancer Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Charlotte : Presbyterian Cancer Center at Presbyterian Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Concord :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Concord : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Durham : Duke Cancer Institute

BKM120 in Metastatic Castration-resistant Prostate Cancer

Durham : Duke Cancer Institute

Pazopanib, Docetaxel, Prednisone Prostate

Durham : Duke University

Safety and Efficacy of Kanglaite Gelcaps in Prostate Cancer

Durham :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Goldsboro : Wayne Memorial Hospital, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greensboro : Moses Cone Regional Cancer Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Greensboro :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Greenville : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Hendersonville : Pardee Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Huntersville :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Pinehurst : FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Raleigh :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Raleigh : Investigational Site Number 840024

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Raleigh : Investigational Site Number 840036

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Raleigh :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Raleigh :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Raleigh :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Rutherfordton : Rutherford Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Statesville : Iredell Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Washington : Investigational Site Number 840011

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Wilmington : PMG Research of Wilmington

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Winston Salem : PMG Research of Winston Salem

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Winston-Salem : Forsyth Regional Cancer Center at Forsyth Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

North Dakota

Bismarck : St. Alexius Medical Center

A research study for patients who have been diagnosed with metastatic, castrate-resistant prostate cancer

Bismarck : Legacy Pharma Research

Prostate Cancer

View More »

Bismark : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Ohio

Akron : Investigational Site Number 840020

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Akron : Investigational Site Number 840026

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Akron : McDowell Cancer Center at Akron General Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Blue Ash : Oncology Hematology Care, Inc.

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Bowling Green : Wood County Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Chillicothe : Adena Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cincinati :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Cincinnati :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Cincinnati : Charles M. Barrett Cancer Center at University Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cincinnati : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Cleveland : Cleveland Clinic

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Cleveland :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Cleveland : Investigational Site Number 840023

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Cleveland :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Cleveland :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Cleveland : Cleveland Clinic

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Cleveland : Cleveland Clinic

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Cleveland : University Hospitals Case Medical Center

SpaceOAR System Pivotal Study

Cleveland :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Columbus : The Mark H. Zangmeister Center

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Columbus : Grant Medical Center Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Mount Carmel Health - West Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Riverside Methodist Hospital Cancer Care

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : CCOP - Columbus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Doctors Hospital at Ohio Health

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Columbus : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Dayton : Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : Grandview Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : Samaritan North Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : CCOP - Dayton

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Dayton : David L. Rike Cancer Center at Miami Valley Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Delaware : Grady Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elyria : Hematology Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Elyria : Community Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Findlay : Blanchard Valley Medical Associates

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Franklin : Middletown Regional Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Wayne Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kettering : Charles F. Kettering Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lancaster : Fairfield Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Lima : Lima Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Marietta : Strecker Cancer Center at Marietta Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Maumee : Northwest Ohio Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Knox Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newark : Licking Memorial Cancer Care Program at Licking Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon : Toledo Clinic - Oregon

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon : St. Charles Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portsmouth : Southern Ohio Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Springfield : Community Hospital of Springfield and Clark County

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sylvania : Flower Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tiffin : Mercy Hospital of Tiffin

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Medical University of Ohio Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : St. Anne Mercy Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : St. Vincent Mercy Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Toledo Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : CCOP - Toledo Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Toledo : Toledo Clinic, Incorporated - Main Clinic

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Troy : UVMC Cancer Care Center at Upper Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wauseon : Fulton County Health Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Westerville : Mount Carmel St. Ann's Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wright-Patterson Afb : United States Air Force Medical Center - Wright-Patterson

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Xenia : Ruth G. McMillan Cancer Center at Greene Memorial Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Zanesville : Genesis - Good Samaritan Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon

Clackamas : Clackamas Radiation Oncology Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Coos Bay : Bay Area Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Grants Pass : Three Rivers Community Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Gresham : Legacy Mount Hood Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Medford : Dubs Cancer Center at Rogue Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Medford : Providence Cancer Center at PMCC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Milwaukie : Providence Milwaukie Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newberg : Providence Newberg Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Oregon City : Willamette Falls Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : OHSU Knight Cancer Institute

BKM120 in Metastatic Castration-resistant Prostate Cancer

Portland : Oregon Health and Science University

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Portland : Oregon Health and Science University Cancer Institute

Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC

Portland : CCOP - Columbia River Oncology Program

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Providence Cancer Center at Providence Portland Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Providence St. Vincent Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Legacy Good Samaritan Hospital & Comprehensive Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Portland : Oregon Health & Science University

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Portland : Oregon Health & Science University

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Portland : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Springfield :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Springfield : Oregon Urology Institute

SpaceOAR System Pivotal Study

Tualatin : Legacy Meridian Park Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Pennsylvania

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

A randomized, double-blind, parallel, placebo-controlled, phase 4, multicenter study to assess efficacy and safety of Vesicare® (solifenacin succinate) to improve urinary continence of subjects after robotic assisted radical prostatectomy. Clinical trial NCT01371994.

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

A randomized, double-blind, phase 2, efficacy and safety study of MDV3100 versus bicalutamide in castrate men with metastatic prostate cancer. Clinical trial NCT01288911.

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

A randomized, double-blind, phase 3 efficacy trial of PROSTVAC-V/F +/- GM-CSF in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Clinical trial NCT01322490.

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

This is a double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in subjects with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen-deprivation therapy. Clinical trial NCT00925600.

Bala Cynwyd : Urologic Consultants of Southeastern Pennsylvania

This is an open-label study of the effect of GTx-758 as a secondary hormone therapy on serum PSA and serum free testosterone levels in men with metastatic castration-resistant prostate cancer maintained on androgen deprivation therapy. Clinical trial NCT01615120.

View More »

Allentown : Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bala Cynwyd : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Bala Cynwyd : Urologic Consultants of SE PA

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Bala Cynwyd : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Bryn Mawr : Urology Health Specialists, LLC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Bryn Mawr : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Dunmore : Investigational Site Number 840032

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lancaster : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Lancaster :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Lancaster :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Lancaster : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Philadelphia : Thomas Jefferson University / Jefferson Urology Associates

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Philadelphia : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Philadelphia : Thomas Jefferson University

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Philadelphia :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Philadelphia : Thomas Jefferson University

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Philadelphia : Fox Chase Cancer Center

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Philadelphia : Albert Einstein Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Philadelphia :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Philadelphia : Hospital of the University of Pennsylvania/Abramson Cancer Center

Safety Study of MGA271 in Refractory Cancer

Pittsburgh :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Pittsburgh :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

State College :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Rhode Island

Pawtucket : Investigational Site Number 840006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Pawtucket : Investigational Site Number 840007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

South Carolina

Anderson : AnMed Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Charleston : Medical University of South Carolina

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Charleston : Medical University of South Carolina

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer

Charleston : Hollings Cancer Center at Medical University of South Carolina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Charleston :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

View More »

Columbia : South Carolina Oncology Associates

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Easley : Cancer Centers of the Carolinas - Easley

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Greenville Hospital System University Medical Center

A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

Greenville : Cancer Centers of the Carolinas

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Greenville :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Greenville : Cancer Centers of the Carolinas - Eastside

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Cancer Centers of the Carolinas - Faris Road

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Cancer Centers of the Carolinas - Grove Commons

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : CCOP - Greenville

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Greenville Hospital Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Bon Secours St. Francis Health System

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greenville : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Greenwood : Self Regional Cancer Center at Self Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greer : Matrix Research, LLC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Greer : Cancer Centers of the Carolinas - Greer Medical Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Greer : Cancer Centers of the Carolinas - Greer Radiation Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Myrtle Beach :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Myrtle Beach : Investigational Site Number 840037

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Myrtle Beach : Carolina Urologic Research Center

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Myrtle Beach :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Myrtle Beach :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Myrtle Beach : Carolina Urologic Research Center

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Myrtle Beach : Carolina Urologic Research Center

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Myrtle Beach : 21st Century Oncology

SpaceOAR System Pivotal Study

Myrtle Beach : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Seneca : Cancer Centers of the Carolinas - Seneca

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : Cancer Centers of the Carolinas - Spartanburg

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : Gibbs Regional Cancer Center at Spartanburg Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spartanburg : CCOP - Upstate Carolina

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

South Dakota

Sioux Falls : Sanford Cancer Center at Sanford USD Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Watertown :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Tennessee

Nashville : Sarah Cannon Research Institute

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

View More »

Chattanooga : Investigational Site Number 840025

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Chattanooga : Investigational Site Number 840028

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Chattanooga : Chattanooga Oncology and Hematology Associates

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Chattanooga : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Cookeville : Cookeville Regional Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Germantown : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Knoxville : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Memphis :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Memphis : The West Clinic

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Memphis : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Nashville : Tennessee Oncology, PLLC

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Nashville : Urology Associates, PC

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Nashville :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Nashville : Urology Associates, P.C.

Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T

Nashville :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Nashville : Sarah Cannon Research Institute

Safety Study of MGA271 in Refractory Cancer

Nashville :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Nashville : Vanderbilt University

Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer

Texas

Amarillo : Harrington Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Amarillo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Austin : The Hospital at Westlake Medical Center

Real Time Microscopic Imaging During Robot Assisted Prostate Cancer Surgery

Bedford : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Carollton : Texas Urology

A 2 Part Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer

View More »

Carrollton : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Corpus Christi : Investigational Site Number 840012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Dallas : Urology Clinics of North Texas

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Dallas :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Dallas :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Dallas : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Fort Sam Houston : Brooke Army Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ft. Worth : Center for Cancer and Blood Disorders, PC

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Galveston : University of Texas Medical Branch

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : University of Texas Vanguard Urologic Research Foundation

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Houston : The University of Texas M D Anderson Cancer Center

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Houston : UT MD Anderson Cancer Center

Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy

Houston : UT MD Anderson Cancer Center

Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone

Houston : UT MD Anderson Cancer Center

Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer

Houston : UT MD Anderson Cancer Center

Maximum Androgen Depletion

Houston : UT MD Anderson Cancer Center

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Houston : UT MD Anderson Cancer Center

Neoadjuvant Axitinib in Prostate Cancer

Houston : UT MD Anderson Cancer Center

Neoadjuvant Ipilimumab in Prostate Cancer

Houston : Dr. Irving Fishman's Office

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Houston : Dr. Ned Stein's Office

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Houston : Ben Taub General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : Baylor University Medical Center - Houston

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : M. D. Anderson Cancer Center at University of Texas

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston : Veterans Affairs Medical Center - Houston

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Houston :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Houston : University of Texas MD Anderson Cancer Center

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Houston : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Houston : UT MD Anderson Cancer Center

TKI258 in Castrate Resistant Prostate Cancer

Laredo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Round Rock :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

San Antonio : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

San Antonio : Urology San Antonio Research, PA

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

San Antonio : Urology San Antonio Research

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

San Antonio : Urology of San Antonio Research

Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling

San Antonio : University Hospital - San Antonio

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : University of Texas Health Science Center at San Antonio

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : Veterans Affairs Medical Center - San Antonio (Murphy)

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio : Cancer Therapy and Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

San Antonio :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

San Antonio : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Temple : CCOP - Scott and White Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tomball : Texas Urology Specialists

Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer

Utah

American Fork : American Fork Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Cedar City : Sandra L. Maxwell Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Logan : Logan Regional Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Murray : Jon and Karen Huntsman Cancer Center at Intermountain Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Ogden : Val and Ann Browning Cancer Center at McKay-Dee Hospital Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Provo : Utah Valley Regional Medical Center - Provo

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Saint George : Dixie Regional Medical Center - East Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : Huntsman Cancer Institute at University of Utah

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : LDS Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City : Utah Cancer Specialists at UCS Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Salt Lake City :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Salt Lake City : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Salt Lake City : For information concerning this clinical site, please contact Nymox at 800-936-9669.

Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer

Virginia

Fairfax : Virginia Cancer Specialists, PC

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Fairfax : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Fredericksburg : Fredericksburg Oncology, Incorporated

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Newport News : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Norfolk :

A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)

View More »

Norfolk :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Richmond : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Richmond : Virginia Cancer Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Richmond :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Salem : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Virginia Beach : Urology of Virginia

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Virginia Beach :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Virginia Beach : Urology of Virginia, PLLC

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Virginia Beach : Urology of Virginia, PLLC

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Virginia Beach : Urology of Virginia

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Virginia Beach : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Washington

Seattle : University of Washington- Seattle Cancer Care Alliance

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

View More »

Anacortes : Island Hospital Cancer Care Center at Island Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bellingham : St. Joseph Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Bremerton : Olympic Hematology and Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Burien : Seattle Urology Research Center

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Burien : Highline Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Centralia : Providence Centralia Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Everett : Providence Regional Cancer Partnership

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Federal Way : St. Francis Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Issaquah : Swedish Medical Center - Issaquah Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kennewick : Columbia Basin Hematology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Kirkland : Cascade Cancer Center at Evergreen Hospital Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Mount Vernon : Skagit Valley Hospital Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Olympia : Providence St. Peter Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Poulsbo : Harrison Poulsbo Hematology and Onocology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Poulsbo : Peninsula Cancer Center

SpaceOAR System Pivotal Study

Puyallup : Good Samaritan Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : University of Washington School of Medicine

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Seattle :

A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer

Seattle : Group Health Cooperative

I-125 Versus Pd-103 for Medium Risk Prostate Cancer

Seattle : VA Puget Sound

I-125 Versus Pd-103 for Medium Risk Prostate Cancer

Seattle : University of Washington

Intermittent Chemotherapy With or Without GM-CSF for Metastatic HPRC

Seattle : Seattle Cancer Care Alliance

Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy

Seattle : CCOP - Virginia Mason Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Fred Hutchinson Cancer Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Group Health Central Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Harborview Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Minor and James Medical, PLLC

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Pacific Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Polyclinic First Hill

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Swedish Cancer Institute at Swedish Medical Center - First Hill Campus

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : Virginia Mason Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle : University Cancer Center at University of Washington Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Seattle :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Seattle : Virginia Mason Hospital

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Seattle : Virginia Mason Medical Center

Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402)

Seattle :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Seattle :

Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Seattle : GTx Investigative Site Updated

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Sedro-Woolley : North Puget Oncology at United General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane : Cancer Care Northwest - Spokane South

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane : Evergreen Hematology and Oncology, PS

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Spokane : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Tacoma : Allenmore Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : CCOP - Northwest

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : St. Clare Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : Franciscan Cancer Center at St. Joseph Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Tacoma : MultiCare Regional Cancer Center at Tacoma General Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Vancouver : Legacy Salmon Creek Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Vancouver : Southwest Washington Medical Center Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wenatchee : Wenatchee Valley Medical Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wisconsin

Green Bay : St. Mary's Hospital Medical Center - Green Bay

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : St. Vincent Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : Green Bay Oncology, Limited at St. Mary's Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Green Bay : Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

La Crosse : Gundersen Lutheran Center for Cancer and Blood

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

View More »

Madison : University of Wisconsin

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Madison :

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Madison : University of Wisconsin Carbone Cancer Center

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Madison : University of Wisconsin Carbone Cancer Center

Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer

Madison : University of Wisconsin Carbone Cancer Center

Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer

Madison :

Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer

Madison :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Madison : University of Wisconsin Carbone Cancer Center

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Manitowoc : Holy Family Memorial Medical Center Cancer Care Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Milwaukee :

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Oconto Falls : Green Bay Oncology, Limited - Oconto Falls

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sheboygan : St. Nicholas Hospital

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Sturgeon Bay : Green Bay Oncology, Limited - Sturgeon Bay

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Wyoming

Casper : Rocky Mountain Oncology

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Argentina

Buenos Aires : Investigational Site Number 032002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Rosario : Investigational Site Number 032001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Salta : Investigational Site Number 032003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Santa Fe : Investigational Site Number 032004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Australia

Adelaide : Investigational Site Number 036014

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Albury : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bankstown : Investigational Site Number 036013

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bankstown : Investigational Site Number 036016

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Box Hill : Investigational Site Number 036010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

View More »

Brisbane : Haematology and Oncology Clinics of Australia

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Camperdown : Investigational Site Number 036012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Camperdown : Investigational Site Number 036008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Camperdown : Royal Prince Alfred Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Coffs Harbour : Investigational Site Number 036008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Coffs Harbour : Investigational Site Number 036015

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Concord : Investigational Site Number 036001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Concord : Investigational Site Number 036001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Darlinghurst : St Vincent's Hospital, Sydney

A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer

Elizabeth Vale : Investigational Site Number 036015

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Fitzroy : Investigational Site Number 036009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Fitzroy : Investigational Site Number 036017

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Garran : Investigational Site Number 036007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Garran : The Canberra Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Heidelberg : Austin Health

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Heidelberg West : Investigational Site Number 036005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Herston : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Herston : Investigational Site Number 036003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Hobart : Royal Hobart Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Hobart : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Hornsby : Investigational Site Number 036010

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kogarah : St George Public Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Kogarah : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Kurralta Park : Investigational Site Number 036012

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kurralta Park : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Malvern : Investigational Site Number 036002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Milton : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Parkville : Investigational Site Number 036002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Port Macquarie : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Randwick :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Randwick : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Richmond : Epworth Healthcare

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Ringwood East : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Saint Leonards : Royal North Shore Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

South Brisbane : Investigational Site Number 036006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

South Brisbane : Investigational Site Number 036009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

South Brisbane : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Subiaco : Investigational Site Number 036016

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Subiaco : Investigational Site Number 036011

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Toowoomba : Radiation Oncology Queensland

PROstate Cancer Imaging, Treatment and Toxicity (PROCITT)

Wahroonga : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Wahroonga : Investigational Site Number 036003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Wahroonga : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Westmead : Westmead Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Westmead : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Wodonga : Investigational Site Number 036004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Wodonga : Investigational Site Number 036013

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Wondonga : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Woodville South : The Queen Elizabeth Hospital

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Woolloongabba : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Austria

Graz : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Innsbruck : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Linz : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Salzburg : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

St Poelten : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

View More »

Vöcklabruck : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wein : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Wels : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wien : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wien : Ludwig Boltzmann-Institute for Applied Cancer Research

Sipuleucel-T Manufacturing Demonstration Study

Wien : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Belarus

Minsk : Investigational Site Number 112002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Minsk : Investigational Site Number 112001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Vitebsk : Investigational Site Number 112004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Belgium

Aalst : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Aalst : Onze-Lieve-Vrouwziekenhuis

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Aalst : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Antwerpen : Investigational Site Number 056007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Antwerpen : Site: 5

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

View More »

Antwerpen : Site: 9

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Antwerpen : Site: 14

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Antwerpen : Site: 4

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Antwerpen : Site: 8

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Bonheiden : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bonheiden : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Brasschaat : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brugge : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brugge : AZ Sint-Jan AV

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Brussel : Investigational Site Number 056008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Brussel : Site: 13

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Brussels : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bruxelle : Hôpital Erasme

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bruxelles : Investigational Site Number 056001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bruxelles : Investigational Site Number 056002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bruxelles : Site: 23

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Bruxelles : Université Catholique de Louvain

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Charleroi : Investigational Site Number 056009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Edegem : Investigational Site Number 056014

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Eupen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Gent : Investigational Site Number 056003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Gent : Site: 11

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Gent : UZ Gent

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Gent : AZ Maria Middelares

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Gent : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Ghent : University Hospital Ghent

The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate

Gilly : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Haine-Saint-Paul : Investigational Site Number 056016

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hasselt : Investigational Site Number 056005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ieper : Site: 21

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Ieper : Regionaal Ziekenhuis Jan Yperman VZW

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Izegem : Site: 20

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Kortijk : Site: 25

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Kortrijk : AZ Groeninge - Campus Sint-Maarten

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Leuven : University Hospitals Leuven

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Leuven : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Libramont : Investigational Site Number 056010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Liège : Investigational Site Number 056013

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Liège : Site: 38

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Liège : CHU de Liège

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Liège : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Mechelen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Merksem : Site: 33

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Namur : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Oostende : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Oostende : Site: 31

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Oostende : AZ Damiaan

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Ottignies : Investigational Site Number 056011

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Oudenaarde : Site: 17

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Roeselare : Investigational Site Number 056004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Roeselare : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Sint Truiden : Site: 37

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Sint-Niklaas : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Tienen : Site: 18

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Turnhout : Investigational Site Number 056006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Turnhout : Site: 1

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients

Verviers : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Yvoir : Investigational Site Number 056012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bosnia and Herzegovina

Sarajevo : Klinicki Centar Univerziteta Sarajevo - Klinika za gastroenterohepatologiju

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Brazil

Curitiba : Investigational Site Number 004

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Fortaleza : Investigational Site Number 076016

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ijui : Investigational Site Number 076012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Mogi Das Cruzes : Investigational Site Number 076015

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Passo Fundo : Investigational Site Number 076006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

View More »

Porto Alegre : Investigational Site Number 076014

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Porto Alegre : Investigational Site Number 076001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Porto Alegre : Investigational Site Number 076002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Porto Alegre : Investigational Site Number 005

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Rio De Janeiro : Investigational Site Number 076010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Rio De Janeiro : Investigational Site Number 076004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Rio de Janeiro : Multi-Imagem and CDPI - Clínica de Diagnóstico por Imagem

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Salvador : Investigational Site Number 076007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Santo Andre : Investigational Site Number 001

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Sao Jose Do Rio Preto : Investigational Site Number 076003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Jose Do Rio Preto : Investigational Site Number 076009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076013

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sao Paulo : Investigational Site Number 076005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

São Paulo : Investigational Site Number 002

Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

Uberlandia : Investigational Site Number 076003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Bulgaria

Pleven :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Plovdiv : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Plovdiv :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Shumen :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Sofia : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

View More »

Varna :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Canada

Toronto, Ontario : Princess Margaret Hospital

An Open-Label, Dose-Escalation, Phase 1 Study of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients with Advanced Nonhematologic Malignancies.

View More »

Abbotsford : Dr. George Vrabec

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Abbottsford : Site Reference ID/Investigator# 56448

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Barrie : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Barrie : The Male/Female Health and Research Centre

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Barrie : Site Reference ID/Investigator# 56450

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Brampton : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Brampton : Dr. Stanley Flax

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Brampton : Dr. Jonathan Giddens

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Brampton : Site Reference ID/Investigator# 54902

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Brantford : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Brantford : Brantford Urology Research

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Brantford : Site Reference ID/Investigator# 54543

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Burlington : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Burlington : G. Kenneth Jansz Medicine Professional Corporation

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Burlington : Site Reference ID/Investigator# 54904

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Burlington : Site Reference ID/Investigator# 57123

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Calgary : Tom Baker Cancer Centre

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Calgary : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Chicoutimi : Site Reference ID/Investigator# 57032

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Edmonton : Cross Cancer Institute

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Edmonton :

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Edmonton : Cross Cancer Institute

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Edmonton : Cross Cancer Institute

Seed Movement in Prostate Brachytherapy Implants: Clinical Measurement and Dosimetric Consequences

Gatineau : Hôpital de Gatineau

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Granby : Site Reference ID/Investigator# 55512

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Greenfield Park : Investigational Site Number 124002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Greenfield Park : Urology South Shore Research

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Greenfield Park : Urology South Shore Research Inc.

Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year

Greenfield Park : Site Reference ID/Investigator# 56447

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Guelph : Dr. Eric Hirshberg

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Guelph : Site Reference ID/Investigator# 56452

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Halifax : QEII Health Sciences Center

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Halifax : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Hamilton : Juravinski Cancer Centre at Hamilton Health Sciences

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Hamilton : Juravinski Cancer Centre

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Kelowna : BCCA - Cancer Centre for the Southern Interior

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Kelowna : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Kelowna : Southern Interior Medical Research Inc.

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Kelowna : Site Reference ID/Investigator# 56446

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Kelowna :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Kingston : Cancer Centre of Southeastern Ontario at Kingston

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Kingston : Kingston Regional Cancer Centre

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Kitchener : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Laval : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Laval : Polyclinique Med Concorde

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Laval : Site Reference ID/Investigator# 54903

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

London : London Regional Cancer Program

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

London : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

London : Investigational Site Number 124002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

London : Site Reference ID/Investigator# 54907

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

London : London Regional Cancer Program

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

London : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Mississauga : Investigational Site Number 124007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Moncton : Investigational Site Number 124005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Montreal : Centre hospitalier de l'Universite de Montreal (CHUM)

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate

Montreal : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Montreal : CHUM-Notre- Dame

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Montreal : Hôpital Maisonneuve-Rosemont

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Montreal : Jewish General Hospital

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Montreal : Investigational Site Number 124003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Montreal : Site Reference ID/Investigator# 74493

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Montreal : Site Reference ID/Investigator# 75313

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Montréal : CHUM-Hospital Notre-Dame

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Newmarket : Dr. Morrie Liquornik

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Newmarket : Site Reference ID/Investigator# 54909

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

North York : Toronto Urology Clinical Study Group

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

North York : Site Reference ID/Investigator# 54908

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Oakville : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Oakville : Dr. Richard Casey

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Oakville : Site Reference ID/Investigator# 54542

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Oshawa : Investigational Site Number 124001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Oshawa : R. S. McLaughlin Durham Regional Cancer Center at Lakeridge Health Oshawa

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Oshawa : Site Reference ID/Investigator# 61303

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Ottawa : Investigational Site Number 124003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ottawa : The Ottawa Hospital Regional Cancer Centre

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Owen Sound : Investigational Site Number 124005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Owen Sound : Dr. Todd Webster

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Owensound : Site Reference ID/Investigator# 56449

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Peterborough : Site Reference ID/Investigator# 56917

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Peterborough : Site Reference ID/Investigator# 61722

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Pointe-Claire : Site Reference ID/Investigator# 56445

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Quebec : Investigational Site Number 124004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Quebec : CHUQ- Hotel-Dieu de Quebec

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Regina : Allan Blair Cancer Centre

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Richmond Hill : Site Reference ID/Investigator# 64145

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Scarborough : Dr. Allan Abramovitch

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Scarborough : Site Reference ID/Investigator# 54906

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Scarborough : Site Reference ID/Investigator# 54905

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Sherbrooke : CHUS - Hôpital Fleurimont - Sherbrooke

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Surrey : Andreou Research

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Surrey, : Site Reference ID/Investigator# 56443

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Toronto : Univ. Health Network-Princess Margaret Hospital

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Toronto : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Toronto : Investigational Site Number 124006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Toronto : Sunnybrook Health Sciences Centre

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Toronto : Sunnybrook Health Sciences Centre, Odette Cancer Centre

Focal Salvage HDR Brachytherapy for the Treatment of Prostate Cancer

Toronto : Site Reference ID/Investigator# 56451

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Toronto : Site Reference ID/Investigator# 57762

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Toronto : Site Reference ID/Investigator# 60843

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Toronto : Site Reference ID/Investigator# 56444

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Toronto :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Toronto :

Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Trois-Rivieres : Site Reference ID/Investigator# 56453

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Trois-Rivières : Centre Hospitalier régional de Trois-Rivières

Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis

Val d'Or : Site Reference ID/Investigator# 55513

Real Life Evaluation of Lupron in the Management of Prostate Cancer: A Canadian Post Marketing Observational Study

Vancouver : BCCA - Vancouver Cancer Centre

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer

Vancouver :

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Vancouver : British Columbia Cancer Agency

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Vancouver : BC Cancer Agency

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Vancouver : BCCA - Vancouver Cancer Centre

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Vancouver :

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

Vancouver :

Study of MDV3100 as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Victoria : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Victoria : Dr. Steinhoff Clinical Research

Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists

Chile

Santiago : Investigational Site Number 152005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Santiago : Investigational Site Number 152002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Santiago : Investigational Site Number 152004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Viña Del Mar : Investigational Site Number 152001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

China

Beijing : Investigational Site Number 156005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Beijing : Peking University People's Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Beijing : Beijing Hospital of Ministry of Health

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Beijing : Peking Union Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Beijing : Peking University 3rd Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

View More »

Beijing :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Changchun : 1st Hospital of Jilin University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Changsha : Hunan Cancer Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Changsha : Hunan Province People's Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Chengdu : People's Hospital of Sichuan

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Chengdu :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Chongqing :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Guangzhou :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Hangzhou : 2nd Hospital Affiliated to Zhejiang University Medical School

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Hangzhou :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Jinan :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Lanzhou : 1st Hospital of Lanzhou University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Nanchang : 1st Affiliated Hospital of Nanchang University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Nanjing : 1st Affiliated Hospital of Nanjing Medical University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Nanjing : Drum Tower Hospital Affiliated to Nanjing University Medical School

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Shanghai : Investigational Site Number 156002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Shanghai : Investigational Site Number 156003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Shanghai : Investigational Site Number 156004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Shanghai : Shanghai 5th People's Hospital affilicated to Fudan University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Shanghai : Shanghai Changhai Hospital

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Shanghai : Fudan University Shanghai Cancer Center

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Shanghai : Huashan Hospital of Fudan University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Shanghai :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Shenyang : 1st Hospital Affiliated to China Medical University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Suzhou : 2nd Hospital Affiliated to Suzhou University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Tianjin : 2nd Hospital of Tianjin Medical University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Tianjin :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Wuchang : Renmin Hospital of Wuhan University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Wuhan : Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Wuhan : Zhongnan Hospital of Wuhan University

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Wuhan :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Wuxi : 1st People's Hospital of Wuxi

One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population

Czech Republic

Benesov : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Brno : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Brno : Investigational Site Number 203002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Hradec Králové : Fakultni nemo Hradec Králové

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Jindrichuv Hradec : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

View More »

Kromeriz : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Liberec : Krajská nemocnice Liberec a.s.

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Novy Jicin : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Novy Jicin : Investigational Site Number 203003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Olomouc : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Olomouc : Investigational Site Number 203001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Olomouc : University Hospital Olomouc

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Praha 2 : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Praha 2 : Investigational Site Number 203004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Praha 4 : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Praha 6 : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Usti nad Labem : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Zlin : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Zlín : Krajská nemo. T.Bati, a. s.

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Znojmo : Nemocnice Znojmo

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Znojmo : Oddeleni Radiacni a Klinicke Onkologie Nemocnice Znojmo

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Denmark

Aalborg : Aalborg Sygehus

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Ålborg : Investigational Site Number 208004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Fredericia : Fredericia Hospital, Sygehus Lillebaelt

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Herlev : Investigational Site Number 208002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Herlev : Herlev Hospital

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

View More »

Holstebro : Holstebro Sygehus

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Kobenhavn : Rigshospitalet

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

København Ø : Investigational Site Number 208001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Odense C : Investigational Site Number 208003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Viborg : Regionhospitalet Viborg

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Finland

Helsinki : Investigational Site Number 246002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Helsinki : Docrates clinic

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Helsinki : Helsinki University Central Hospital

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Helsinki : Helsinki University Central Hospital

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Joensuu : Pohjois-Karjalan keskussairaala

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

View More »

Kuopio : Investigational Site Number 246001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kuopio : Kuopio University Hospital

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Kuopio : Kuopio University Hospital

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Tampere : Tampere University Hospital

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Tampere : Tampere University Hospital

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Turku : Investigational Site Number 246003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

France

Aix en Provence : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Aix en Provence cedex 01 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Amiens : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Angers : CHRU Angers

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Angers : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

View More »

Athis Mons : Centre Hospitalier d'Athis Mons site Caron

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Aubervilliers : Hopital Tenon

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Avignon : Investigational Site Number 250005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Avignon : Clinique Rhone Durance

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bayonne : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Besançon Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Besancon : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Besançon : CHU Saint-Jacques

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Besancon Cedex : Investigational Site Number 250010

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Bordeaux : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bordeaux : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bordeaux Cedex : Investigational Site Number 250002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Boulogne sur Mer Cédex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bourg en Bresse : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Brive la Gaillarde : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Caen Cedex 05 : Investigational Site Number 250006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Caen cedex 05 : Centre François Baclesse

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Clermont Ferrand : Centre Hospitalier Laennec

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Clermont Ferrand : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Colmar Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Dijon : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Dijon : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Evry : Ramsay Sante

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Hyeres : Investigational Site Number 250008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

La Roche Sur Yon : Investigational Site Number 250001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

La Roche sur Yon : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

La Seyne Sur Mer : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Le Mans : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Le Mans Cedex 9 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lille : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Longjumeau cedex 1 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lyon : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Lyon : Investigational Site Number 250005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lyon : Groupement hospitalier Edouard Herriot

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Lyon cédex 08 : Centre Léon Bérard

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Marseille : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Marseille : CHU Nord

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Marseille : Hopital de la Conception

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Marseille : Cabinet Médical 65 prado

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Marseille : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Melun : Polyclinique Saint-Jean

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Mont de Marsan : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Montauban : Clinique du Pont de Chaume

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Montpellier : Clinique Beausoleil

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nancy : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Nancy : Centre d'Urologie de Nancy

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nanterre : Hôpital Max Fourestier

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nantes : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Nantes Cedex 2 : Investigational Site Number 250002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Nice Cedex 2 : Centre Antoine Lacassagne

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Nimes : Investigational Site Number 250004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Nîmes : Groupe hospitalo-universitaire Caremeau

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Niort : Centre Hospitalier Georges Renon

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Périgueux cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Paris : Investigational Site Number 250010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Paris : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Paris Cedex 05 : Investigational Site Number 250003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Paris Cedex 05 : Institut Curie

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Paris Cedex 10 : Investigational Site Number 250004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Paris Cedex 15 : Investigational Site Number 250001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Paris Cedex 20 : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Paris Cedex 5 : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Pierre Benite : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Ploemeur : Clinique du Ter

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Poitiers Cedex : Investigational Site Number 250007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Poitiers Cedex : Centre Hospitalier Universitaire de Poitiers Hôpital de la Milétrie

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Pontoise : Clinic De L'Europe

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Pontoise Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Pringy Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Reims : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Reims : Investigational Site Number 250007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Reims : Investigational Site Number 250009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Reims : Institut Jean-Godinot

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Reims Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rennes : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rennes : Hopital Pontchaillou

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Rennes : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Rouen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint Brieuc Cedex : Investigational Site Number 250006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Saint Grégoire cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint Herblain : Institut de Cancérologie de l'Ouest - René Gauducheau

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Saint Quentin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Saint-Herblain : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Soissons Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Soyaux : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Strasbourg : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Suresnes : Investigational Site Number 250008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Suresnes :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Suresnes : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Toulon : Clinique Saint Michel

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Toulouse : Clinique St Jean Languedoc

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Toulouse Cedex : Investigational Site Number 250003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Toulouse Cedex 03 : Investigational Site Number 250011

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Tours : Hopital Bretonneau

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Vandoeuvre les Nancy : CHU Brabois

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Vichy cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villefranche Sur Saone Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villejuif : Investigational Site Number 250001

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Villejuif : Investigational Site Number 250009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Villejuif : Institut Gustave Roussy

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Villejuif Cedex : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Villejuif Cedex : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Germany

Aachen : Investigational Site Number 276003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Aachen : Investigational Site Number 276003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Augsburg : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bad Bergzabern : Praxis Dr. Schlichter

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bautzen : Praxis Dr. Markus Hentschel

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

View More »

Berlin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Berlin : Investigational Site Number 276005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Braunschweig : Urologie im Schlosscarree

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bremerhaven : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bremerhaven : Praxis Dr. Ahmad Haider

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Chemnitz : Urologie Chemnitz

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Chemnitz : Praxis Dr. Krieger

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dachau : Gemeinschaftspraxis fur Urologie

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dinslaken : Klinikpraxis fur Urologie

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dresden : Investigational Site Number 276007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Düsseldorf : Investigational Site Number 276004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Düsseldorf : Investigational Site Number 276001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Erlangen : Investigational Site Number 276001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Erlangen : Investigational Site Number 276004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Freiburg im Breisgau : Clinic SanaFontis

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

Goslar : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Halle/Saale : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Hamburg : Investigational Site Number 276005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hamburg : Investigational Site Number 276011

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hamburg : Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Hamburg : Praxis Dr. Schönfelder

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Homburg : Investigational Site Number 276010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Homburg : Investigational Site Number 276002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Köln : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Kassel : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Kiel : Gemeinschaftspraxis Urologie

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Kiel : Urologische Gemeinschaftspraxis

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Kirchheim : Gemeinshaftspraxis Rudolph & Wörner

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Koln : Praxis Dr. Thomas Harms

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Leipzig : Vituro

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Mannheim : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Marburg : Praxis Alexander von Keitz

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

München : Investigational Site Number 276006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

München : Investigational Site Number 276006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Neunkirchen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Nienburg : Praxis Dr. Peczat

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nürtingen : Investigational Site Number 276012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Planegg : UCM GmbH

Treatment of Prostate Cancer With Firmagon®

Planneg : Studienzentrum München-Planegg

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Reutlingen : Urologische Gemeinschaftspraxis

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Stralsund : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Tostedt : Praxis Dr. Jan Franz

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Tübingen : Investigational Site Number 276008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Würselen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Wuppertal : Investigational Site Number 276002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Wuppertal : Praxis fur Urologie

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Greece

Alexandroupoli : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Athens : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Athens : Ippokrateio Hospital of Athens

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Athens : "Agios Savas" Anticancer-Oncology Hospital of Athens

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Athens : Korgialenio-Benakio

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

View More »

Herakleion : Pe. Pa.G.N:I Hospital

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Heraklion : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Kalamata : General hospital of Kalamata

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Larissa : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Larissa : University Hospital of Larissa

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Marousi : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Patra : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Patras : University General Hospital of Patras

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Thessaloniki : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Thessaloniki : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Thessaloniki : "G. Gennimtas" General Hospital of Thessaloniki

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Thessaloniki : Papageorgiou General Hospital of Thessaloniki

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Hungary

Baja : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Budapest : Jahn Ferenc South Pest Hospital, Department of Urology

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Budapest : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Budapest : Investigational Site Number 348001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Budapest : Investigational Site Number 348004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

View More »

Budapest : Investigational Site Number 348005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Budapest : Országos Onkológiai Intézet

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Budapest : Semmelweis Egyetem Általános Orvostudományi Kar

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Gyor : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Gyula : Pándy Kálmán Megyei Kórház

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Kiskunhalas : Kiskunhalasi Semmelweis Kórház Kht.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Miskolc : Investigational Site Number 348006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Miskolc : Borsod Abaúj Zemplén Megyei Kórház és Egyetemi Oktató Kórház

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Miskolc : Miskolci Semmelweis Ignác Egészségügyi Központ és Egyetemi Oktató Kórház Nonprofit Kft

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nyiregyhaza : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Pécs : Investigational Site Number 348003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sopron : Soproni Erzsébet Oktató Kórház

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Szeged : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

India

Ahmedabad : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Aurangabad : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Ludhiana : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Madurai : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Nashik : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

View More »

New Delhi : Vardhaman Mahavir Medical College And Safdarjung Hospital

International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer

Ireland

Cork : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Dublin : Beacon Hospital

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dublin : Beaumont Hospital

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Dublin : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Galway : University College Hospital

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Israel

Haifa : Bnai Zion medical center

A Novel 3D Navigation Technology for Improved TRUS Prostate Biopsy

Kfar Saba : Investigational Site Number 376004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Petah-Tikva : Investigational Site Number 376003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tel Aviv : Investigational Site Number 376002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tel Aviv : Ichilov Medical Center

Evaluation of the Safety and Efficacy of the BioProtect Balloon in Prostate Cancer Subjects Undergoing Radiotherapy

View More »

Tel Hashomer : Sheba Medical Center

Safety Evaluation of ExAblate MRgFUS for Prostate Cancer

Italy

Ancona : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Arezzo : Investigational Site Number 380001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Avellino : Medical Consulting Center S.r.l.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Aviano : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bari : Investigational Site Number 380004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

View More »

Brindisi : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Catanzaro : Azienda Ospedaliera Mater Domini di Catanzaro

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Cefalù PA : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Cesena : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Cremona : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Faenza : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Genova : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Lugo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Meldola : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Milano : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Napoli : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Novara : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Orbassano : Investigational Site Number 380003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Orbassano : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Padova : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Padova : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Pavia : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Pisa : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Ravenna : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Reggio Calabria : Azienda Ospedaliera "Bianchi-Melacrino-Morelli"

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Rimini : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Roma : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Roma : Investigational Site Number 380005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Roma : Istituto Nazionale Tumori "Regina Elena"

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Rome : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Rozzano : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Terni : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Torino : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Torino : Azienda Ospedaliero Universitaria "San Giovanni Battista di Torino"

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Torino : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Trento : Investigational Site Number 380002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Japan

Asahi :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Asahi :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Bunkyo-Ku : Investigational Site Number 392001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Chiba-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Chiba-Shi : Investigational Site Number 392003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

View More »

Fukuoka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Fukuoka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Fukuoka-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Gifu :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Itabashi-ku :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Kanazawa :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Kanazawa :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Kanazawa-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Kashiwa :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Kashiwa-Shi : Investigational Site Number 392006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kita-adachi-gun :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Kita-Gun :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Kita-Gun :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Koto-Ku : Investigational Site Number 392005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kuki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Kuki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Kurashiki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Kurashiki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Maebashi :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Maebashi N/A :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Maebashi N/A :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Maebashi-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Matsuyama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Matsuyama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Miki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Miki :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Mitaka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Mitaka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Nagoya-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Nigata-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Niigata :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Niigata :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Osaka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Osaka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Osaka Sayama-Shi : Investigational Site Number 392002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Osaka-City :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Osaka-City :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Osaka-Sayama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Osaka-Sayama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Osaka-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Osaka-Shi : Investigational Site Number 392004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Sagamihara :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Sagamihara :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Sakura :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Sakura :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Sakura-Shi :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Sakura-Shi :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Sapporo :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Sapporo :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Sapporo-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Sendai-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Shinjuku-ku :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Shizuoka-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Suita-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Tokyo :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Yokohama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Yokohama :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Yokohama-shi :

A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy

Yokosuka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer

Yokosuka :

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel

Korea, Republic of

Busan :

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Cheongju-Si :

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Seognam-Si, Kyungki-Do :

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Seongnam : Investigational Site Number 410003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Seongnam : Seoul National University Bundang Hospital

Early Start of Oral Sildenafil 100mg for Erectile Dysfunction After Robotic Assisted Laparoscopic Radical Prostatectomy

View More »

Seoul : Investigational Site Number 410004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Seoul : Investigational Site Number 410005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Seoul : Investigational Site Number 410002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Seoul : Investigational Site Number 410001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Latvia

Daugavpils :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Jelgava : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Riga : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Riga :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Malaysia

Kuala Lumpur :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Kuala Lumpur N/A :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Mexico

Acapulco : Investigational Site Number 484007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Aguascalientes : Investigational Site Number 484008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

D.f. : Investigational Site Number 484003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Distrito Federal : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Guadalajara : Investigational Site Number 484004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

View More »

Merida : Investigational Site Number 484009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Queretaro : Investigational Site Number 484005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

San Luis Potosi : Investigational Site Number 484002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tlalpan : Instituto Nacional de Cancerologia

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Zapopan : Investigational Site Number 484006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Netherlands

Amstelveen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Amsterdam : AMC

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Arnhem : Investigational Site Number 528005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Blaricum : Investigational Site Number 528003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Den Haag : MC Haaglanden

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

View More »

Dordrecht : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Eindhoven : Catharina ziekenhuis

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Enschede : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Groningen : UMC Groningen

Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients

Groningen : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Hoofddorp : Investigational Site Number 528004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Leiden : Diaconessenhuis Leiden

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Leiderdorp : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Nieuwegein : St. Antonius Hospital

Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.

Nieuwegein : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Nijmegen : Investigational Site Number 528002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Nijmegen : UMC Nijmegen

Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients

Nijmegen : Radboud University Nijmegen Medical Centre

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Nijmegen : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Purmerend : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Roosendaal : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Rotterdam : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Utrecht : Diakonessenhuis

Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.

Utrecht : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Vlissingen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Woerden : Zuwe Hofpoort Ziekenhuis Woerden, Netherlands

Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.

Zutphen : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Zwolle : Investigational Site Number 528001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Zwolle : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

New Zealand

Christchurch : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Takapuna, North Shore City : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Tauranga : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Whangarei : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Norway

Bergen : Haukeland Universitetssykehus

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Gjettum : Vestre Viken HF, Sykehuset Asker og Baerum

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Oslo : Oslo Universitetssykehus, Aker

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Oslo : Jon R Iversen

Treatment of Prostate Cancer With Docetaxel + Hormonal Treatment Versus Hormonal Treatment in Patients Treated With Radical Radiotherapy

Trondheim : Norwegian University of Science and Technology

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

Peru

Arequipa : Investigational Site Number 604003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

View More »

Lima : Investigational Site Number 604005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lima : Investigational Site Number 604006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Poland

Bialystok : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bydgoszcz : Investigational Site Number 616002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Gdansk : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Gdansk : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Gdansk : Investigational Site Number 616001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

View More »

Gdynia : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Katowice : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Koscierzyna : Investigational Site Number 616003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Koszalin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Krakow : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lodz : Investigational Site Number 616005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lubin : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Lubin : Investigational Site Number 616006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Lublin : SPSK1 Klinika Hematologii

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Myslowice : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Olsztyn : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Olsztyn : Investigational Site Number 616002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Opole : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Poznan : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Poznan : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Poznan : Investigational Site Number 616004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Rybnik : Investigational Site Number 616001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Siedlce : Investigational Site Number 616005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Slupsk : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Szczecin : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Torun : Investigational Site Number 616004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Walbrzych : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Warsaw :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Warszawa : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Wroclaw : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Wroclaw : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Portugal

Coimbra : Investigational Site Number 620003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lisboa : Investigational Site Number 620004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lisboa : Investigational Site Number 620005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Porto : Investigational Site Number 620001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Porto : Investigational Site Number 620002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Puerto Rico

Ponce : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Romania

Alba Iulia : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Alba Iulia : Investigational Site Number 642005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Baia Mare : Investigational Site Number 642006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Baia Mare : Investigational Site Number 642004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Baia-Mare : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

View More »

Brasov : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bucharest : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bucharest : Investigational Site Number 642008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Bucharest :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Bucuresti : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Bucuresti : Investigational Site Number 642008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bucuresti : Investigational Site Number 642009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bucuresti : Investigational Site Number 642005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Bucuresti : Centrul de Diagnostic si Tratament Euromedic Fundeni

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Cluj Napoca : Investigational Site Number 642001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Cluj Napoca : Investigational Site Number 642002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Cluj-Napoca : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Craiova :

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Focsani : Investigational Site Number 642012

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hunedoara : Investigational Site Number 642007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Hunedoara : Investigational Site Number 642007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Onesti : Investigational Site Number 642013

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Oradea : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Ramnicu Valcea : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Targu Mures : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Timisoara : Research Site

Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia

Russian Federation

Arkhangelsk :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Ekaterinburg : Investigational Site Number 643009

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ekaterinburg : Investigational Site Number 643004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Ekaterinburg :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Ivanovo : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

View More »

Moscow : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Moscow : Investigational Site Number 643004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Moscow : Investigational Site Number 643005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Moscow : Investigational Site Number 643006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Moscow : Investigational Site Number 643007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Moscow : Investigational Site Number 643008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Moscow :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Moscow N/A :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Nizhny Novgorod : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Obninsk : Investigational Site Number 643008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Omsk : Investigational Site Number 643003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Pyatigorsk : Investigational Site Number 643002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Pyatigorsk :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Rostov-na-Dony : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Rostov-On-Don :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Ryazan : Investigational Site Number 643007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Sochi :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

St.Petersburg : Investigational Site Number 643001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

St.Petersburg : Investigational Site Number 643010

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stavropol :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

St-Petersburg : Investigational Site Number 643005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tomsk : Investigational Site Number 643001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tula : Investigational Site Number 643003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ufa :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Yaroslavl : Investigational Site Number 643006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Yoshkar-Ola :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Saudi Arabia

Riyadh : King Faisal Specialist Hospital and Research Center

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Slovakia

Bosany : VEBMED, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bratislava : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Bratislava : URO clinic, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bratislava : Univerzitna nemocnica Bratislava

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Bratislava : CUIMED, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

View More »

Galanta : Poliklinika Galanta

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Kosice : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Kosice : MEDICONA s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Levice : UROCENTRUM LEVICE, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Malacky : Poliklinika Malacky

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Martin : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Martin : Univerzitna nemocnica Martin

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Nitra : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Nitra : UROEXAM, spol. s r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Povazska Bystrica : CENTRUM UROLOGIE Povazska Bystrica s.r.o

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Presov : MILAB, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Sala : UROCENTRUM SALA, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Skalica : Nemocnica s poliklinikou Skalica, a.s.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Topolcany : M & M & M, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Trencin : PRIVATNA UROLOGICKA AMBULANCIA s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Vrable : UROREX, s.r.o.

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Slovenia

Celje : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Ljubljana : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Slovenj Gradec : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

South Africa

Cape Town : Investigational Site Number 710003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Cape Town : Department of Urology, Tygerberg Hospital

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Cape Town : New Grootte Schuur Hospital, Division of Urology

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Cape Town : Paarl Medical Centre

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Cape Town : Vergelegen Medi-Clinic

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

View More »

Durban : Investigational Site Number 710002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Eastern Cape : Dr JCM Bahlmann

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Gauteng : Clinical Trial Unit, Room 2-54, Prinshof Medical Campus

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Gauteng : Clinresco Centres (Pty) Ltd

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Gauteng : Pretoria Urology Hospital

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

George : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Johannesburg : Investigational Site Number 710004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Johannesburg : Investigational Site Number 710005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Johannesburg : East Rand Urology Research Unit, Clinix Private Clinic

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Kempton Park : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Klerksdorp : Wilmed Park Hospital

Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer

Paarl : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Port Elizabeth : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Pretoria : Investigational Site Number 710001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Tygerberg : Research Site

A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Spain

Badalona : Investigational Site Number 724003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Barcelona : Investigational Site Number 724001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Barcelona : Investigational Site Number 724007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Barcelona : Investigational Site Number 724001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Barcelona : Investigational Site Number 724002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

View More »

Barcelona : Hospital Clinic i Provincial de Barcelona

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Barcelona : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Barcelona : Fundación IMOR Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Barcelona : H. de la Santa Creu i Sant Pau Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Hospitalet De Llobregat : Investigational Site Number 724003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Hospitalet de Llobregat : ICO Institut Català d'Oncologia-Hospitalet Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

La Coruna : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

La Laguna : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Madrid : Investigational Site Number 724002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Madrid : Investigational Site Number 724008

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Madrid : Investigational Site Number 724004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Madrid : Investigational Site Number 724005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Madrid : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Madrid : H. Ramón y Cajal Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Majadahonda : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Málaga : Investigational Site Number 724006

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Manresa : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Palma De Mallorca : Investigational Site Number 724005

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Palma de Mallorca : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Sabadell : Investigational Site Number 724004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

San Cristobal de la Laguna Santa Cruz : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

San Sebastián : Instituto Oncológico Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Santiago De Compostela : Investigational Site Number 724006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Santiago de Compostela : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Santiago de Compostela : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Sevilla : Investigational Site Number 724007

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Valencia : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Valencia : IVO Instituto Valenciano de Oncología Updated

Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

Valencia : Private practice, La Cañada, Paterna Updated

Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State

Sweden

Gotenborg : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Malmo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Malmö : Investigational Site Number 752003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Malmoe : Urology Dep. Skane Univeristy Hospital

Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer

Orebro : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

View More »

Stockholm : Investigational Site Number 752002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Stockholm : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Umea : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Uppsala : Investigational Site Number 752001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Uppsala : Department of Oncology, University Hospital Uppsala

Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer

Uppsala : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Vaxjo : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Switzerland

Basel : Universitätsspital Basel

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Genolier : IMO Clinique de Genolier

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Lausanne : Centre Hospitalier Universitaire Vaudois

Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer

Zurich : Urozentrum Zürich

Post Authorisation Safety Study (PASS) on Patients With Advanced Prostate Cancer

Taiwan

Kaohsiung : Investigational Site Number 158004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Taiching : Investigational Site Number 158002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Taichung : Investigational Site Number 158002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Taichung City :

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Tainan : Investigational Site Number 158003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

View More »

Taipei : Investigational Site Number 158001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Taipei : Investigational Site Number 158001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Tao-Yuan : Investigational Site Number 158003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Taoyuan County :

A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer

Thailand

Bangkok :

Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer

Tunisia

Ariana : Investigational Site Number 788001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sfax : Investigational Site Number 788004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Sousse : Investigational Site Number 788003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Tunis : Investigational Site Number 788002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Turkey

Ankara : Investigational Site Number 792002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Antalya : Investigational Site Number 792003

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Bornova : Investigational Site Number 792001

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Istanbul : Investigational Site Number 792002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Istanbul : Investigational Site Number 792001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

View More »

Kayseri : Investigational Site Number 792004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Ukraine

Cherkasy : Investigational Site Number 804009

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Dnipropetrovsk : Investigational Site Number 804004

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Donetsk : Investigational Site Number 804010

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Ivano-Frankivsk : Investigational Site Number 804006

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kharkov : Investigational Site Number 804003

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

View More »

Kyiv : Investigational Site Number 804001

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Kyiv : Investigational Site Number 804002

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Lutsk : Investigational Site Number 804007

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Uzhgorod : Investigational Site Number 804005

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Zaporizhzhya : Investigational Site Number 804008

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

United Kingdom

Addlestone : The Crouch Oak Family Practice Updated

GP Extended Action Triptorelin

Ashford : Dr Carter & Partners Updated

GP Extended Action Triptorelin

Aylesbury : Westongrove Research Centre, Aston Clinton Surgery Updated

GP Extended Action Triptorelin

Bath : St James' Surgery Updated

GP Extended Action Triptorelin

Bath : Clinical Research Unit, Oldfield Surgery Updated

GP Extended Action Triptorelin

View More »

Bath : Clinical Research Unit, The Pulteney Practice Updated

GP Extended Action Triptorelin

Bath : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Birmingham : Investigational Site Number 826002

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Birmingham : Queen Elizabeth Hospital

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Birmingham : Queen Elizabeth Hospital

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Birmingham : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Blackpool : Waterloo Medical Centre Updated

GP Extended Action Triptorelin

Brighton : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bristol : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Bury St. Edmunds : Woolpit Health Centre Updated

GP Extended Action Triptorelin

Cambridge : Addenbrookes Hospital Cambridge

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Cambridge : Updated

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Canterbury : Cossington House Surgery Updated

GP Extended Action Triptorelin

Cardiff : Velindre Cancer Centre

Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer

Cardiff : Velindre Cancer Centre

Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001

Chesterfield : Research Office, Avondale Surgery Updated

GP Extended Action Triptorelin

Chippenham : Clinical Research Dept., Rowden Surgery Updated

GP Extended Action Triptorelin

Chippenham : Clinical Research Unit, Hathaway Medical Centre Updated

GP Extended Action Triptorelin

Colchester : Investigational Site Number 826004

Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Corsham : The Porch Surgery Updated

GP Extended Action Triptorelin

East Horsley : The Medical Centre Updated

GP Extended Action Triptorelin

Glasgow : Investigational Site Number 826005